⏳ Final hours! Save up to 60% OFF InvestingProCLAIM SALE

Sanofi SA (SASYn)

Paris
Currency in EUR
91.20
0.00(0.00%)
Closed
SASYn Scorecard
Full Analysis
Has raised its dividend for 25 consecutive years
High dividend Yield
Fair Value
Day's Range
91.2091.20
52 wk Range
81.8098.00
Key Statistics
Edit
Prev. Close
91.2
Open
91.2
Day's Range
91.2-91.2
52 wk Range
81.8-98
Volume
-
Average Volume (3m)
2.72K
1-Year Change
-
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SASYn Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with low price volatility

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Employees
86088
Market
France

Compare SASYn to Peers and Sector

Metrics to compare
SASYn
Peers
Sector
Relationship
P/E Ratio
0.0x−2.5x−0.7x
PEG Ratio
0.00−0.020.00
Price/Book
0.0x0.9x2.6x
Price / LTM Sales
0.0x1.6x3.2x
Upside (Analyst Target)
0.0%17.8%46.4%
Fair Value Upside
Unlock9.9%6.9%Unlock

Analysts' Recommendations

15 Buy
4 Hold
2 Sell
Ratings:
21 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 114.09

(+25.10% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 3.6
Dividend Yield
4.10%
Industry Median 3.76%
Annualised payout
3.7600
Paid annually
5-Years Growth
+4.14%
Growth Streak
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.